Form S-1
Please include disclosure of your controlled company status on the prospectus cover page, the amount of the voting power the controlling shareholder will own following the completion of the offering, and, if true, that you do not intend to comply with certain corporate governance requirements.
Sotera Health Company (also referred to herein as the “Company,” “we,” “our,” “us” or “its”), is a fully integrated provider of mission-critical health sciences, lab services and sterilization solutions with operations primarily in the Americas, Europe and Asia.Read in the reply
The accompanying consolidated financial statements include the assets, liabilities, operating results, and cash flows of the Company and its wholly owned subsidiaries prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information.Rest of the answer
These unaudited interim financial statements should be read in conjunction with the Company’s annual consolidated financial statements and accompanying notes for the year ended December 31, 2019.
The accompanying interim financial statements are unaudited, but reflect all adjustments, consisting of normal recurring adjustments, that, in the opinion of management, are necessary for a fair presentation of the financial statements. The preparation of financial statements in conformity with GAAP requires management to make periodic estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities. We regularly evaluate the accounting policies and estimates used. Actual results could differ from these estimates. The reported results of operations are not necessarily indicative of results of operations for any future period.
We operate and report in three segments, Sterigenics, Nordion and Nelson Labs. We describe our business segments in the Segment Information note. All significant intercompany balances and transactions have been eliminated in consolidation.
Noncontrolling interests represents the noncontrolling stockholders’ proportionate share of the total equity in the Company’s consolidated subsidiaries. As of September 30, 2020, our subsidiaries were wholly owned by us, except for noncontrolling interests of 15% and 33% in our two China subsidiaries. In addition, a 15% noncontrolling interest remains from the August 2018 acquisition of Gibraltar Laboratories, Inc. (now known as Nelson Laboratories Fairfield, Inc.). We consolidate the results of operations of these subsidiaries with our results of operations and reflect the noncontrolling interests in our two China subsidiaries on our consolidated statements of operations and comprehensive income (loss) as “Net income (loss) attributable to noncontrolling interests.”
Our required future purchase of 15% noncontrolling interest in Nelson Laboratories Fairfield, Inc. is considered mandatorily redeemable, and therefore no earnings are allocated to this noncontrolling interest.
In the third quarter of 2020, we identified an immaterial error in previously issued financial statements as a result of incorrectly recording the foreign exchange (gain)/loss in a U.S. dollar denominated loan between a U.S. subsidiary and European subsidiary. We have evaluated this error and concluded it to be immaterial in consideration of the September 30, 2020 financial statements and previously issued financial statements, based on an analysis of quantitative and qualitative factors affecting each prior reporting period. We reflected the correction of this immaterial error within these financial statements for the period ended
September 30, 2020, the effect of which increased foreign exchange (gain)/loss and net income by $2.2 million.
It is not appropriate to directly or indirectly disclaim liability for statements in your registration statement. Accordingly, please delete your statements that the accuracy and completeness of information contained in consultants’ reports and industry publications is not guaranteed, that your internal company analyses have not been verified by any independent source, and that neither you nor the underwriters makeRest of the question
any representation as to the accuracy of such information.
Adoption of New Accounting StandardsRead in the reply
Effective January 1, 2020, we adopted Accounting Standards Update (“ASU”) No. 2016-02, Leases
(“Topic 842”) which was issued by the Financial Accounting Standards Board (“FASB”) in 2016. The new standard requires substantially all leases to be reported on the balance sheet as right-of-use assets and lease obligations. It also increases disclosure of key information about leasing arrangements.Rest of the answer
We adopted the new guidance using the optional transition method, which required application of the new guidance to only leases that existed at the date of adoption. We also elected the “package of practical expedients,” which permitted us to not reassess under the new standard our prior conclusions about lease identification, lease classification and initial direct costs. The adoption of the new standard resulted in the recognition of right-of-use assets and lease liabilities of $47.4 million and $48.9 million as of January 1, 2020, respectively. The standard did not have a material impact on our consolidated statements of operations and comprehensive income (loss) or on our consolidated statements of cash flows.
In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the
Effects of Reference Rate Reform on Financial Reporting. This ASU provides optional guidance for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting due to the cessation of the London Interbank
Offered Rate (“LIBOR”). The amendments in this update are effective for the Company as of March 12, 2020 through December 31, 2022. The Company adopted this standard effective
March 12, 2020. The adoption of this standard had no effect in the nine months ended September 30, 2020, and its future impact will depend on the manner in which the Company and its lenders ultimately address the removal of LIBOR as it relates to the long-term debt arrangements described in the Debt Obligations note.
Accounting Standards Issued But Not Yet Adopted
Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. As an emerging growth company, we have elected to take advantage of the extended transition period for complying with new or revised accounting standards until those standards would otherwise apply to private companies or at which time we conclude it is appropriate to avail ourselves of early adoption provisions of applicable standards. As a result, our results of operations and financial statements may not be comparable to the results of operations and financial statements of other companies who have adopted the new or revised accounting standards.
In June 2016, the FASB issued ASU
2016-13, Financial Instruments—Credit Losses (“ASU 2016-13”): Measurement of Credit Losses on Financial Instruments and subsequently issued additional guidance that modified ASU 2016-13. The standard requires an entity to change its accounting approach in determining impairment of certain financial instruments, including trade receivables, from an
“incurred loss” to a “current expected credit loss” model. The standard will be effective for private companies for fiscal years beginning after December 15, 2022, including interim periods within such fiscal years. Early adoption is permitted. We are currently assessing the effect that ASU 2016-13 will have on our financial position, results of operations, and disclosures.
In December 2019, the FASB issued ASU 2019-12—Income Taxes (Topic 740): Simplifying the Accounting for Income
Taxes. The standard simplifies the accounting for income taxes and makes a number of changes meant to add or clarify guidance on accounting for income taxes. This update is effective for annual and interim financial statement periods beginning after December 15, 2022, with early adoption permitted in any interim period for which financial statements have not yet been filed. We are currently assessing the effect that ASU 2019-12 will have on our financial position, results of operations and disclosures.
We note the statement the global population is expected to increase by 1 billion people by 2025 and of that 1 billion, approximately 300 million will reach age 65 or older. Please clarify whether the 300 million will reach the age of 65 by the year 2025 or sometime after that. We also note the estimated global healthcare costs of approximately $4 trillion in 2019 and projected to reach more than $6 trillion by 2027.Rest of the question
Please highlight what fraction of that estimate is represented by services you provide.
The following table shows disaggregated net revenues from contracts with external customers by timing of revenue and by segment for the nine months endedRead in the reply
September 30, 2020 and 2019:
Nine months ended September 30, 2020
Sterigenics
Nordion
Nelson Labs
Consolidated
Point in time
363,955
86,034
449,989
Over time
151,324
Nine months ended September 30, 2019
350,387
91,869
442,256
142,586
Contract Balances
September 30, 2020 and December 31, 2019, contract assets included in “Prepaid expenses and other current assets” on the consolidated balance sheets totaled approximatelyRest of the answer
$14.0 million and $8.5 million, respectively, resulting from revenue recognized over time in excess of the amount billed to the customer.
When we receive consideration from a customer prior to transferring goods or services under the terms of a sales contract, we record deferred revenue, which represents a contract liability. Deferred revenue totaled $4.1 million and $3.6 million at September 30, 2020 and December 31,
2019, respectively. We recognize deferred revenue after we have transferred control of the goods or services to the customer and all revenue recognition criteria are met.
We note your statement that you are "a respected industry partner for regulators as they are defining industry standards of safety for the future." Please provide the basis for this statement and the similar statement on page 109 in which you state you have established credibility and trust with regulators and standards writing organizations.
Iotron Industries Canada, Inc. AcquisitionRead in the reply
On
July 31, 2020, we acquired Iotron Industries Canada, Inc. (“Iotron”) for approximately $106.3 million, subject to customary working capital and other adjustments. Iotron is an independent contact sterilizer with two North
American locations in Vancouver, Canada, and Columbia City, Indiana. Each location uses proprietary high energy electron beam technology to process products for orthopedic, medical device, plastics, and agricultural businesses.Rest of the answer
As part of this acquisition, we also acquired Iotron’s 60% equity ownership interest in a joint venture to construct an E-beam facility in Alberta, Canada. The E-beam facility is under construction and is not expected to be operating until mid-2021. The joint venture is accounted for using the equity method. The acquisition was financed by the issuance of $100.0 million of 1st lien notes due 2026. Refer to the Debt Obligations note for additional details.
The opening balance sheet for the Iotron acquisition reflects the net tangible and intangible assets acquired and liabilities assumed at their estimated fair values at the acquisition date.
The preliminary estimated fair value of the underlying acquired assets and assumed liabilities at July 31, 2020, the date of the Iotron acquisition, was as follows:
Preliminary allocation of purchase price to the fair value of net assets acquired (net of cash acquired):
Amounts
Recognized as of July 31,
64,235
Other intangible assets
16,427
Property, plant, and equipment
13,799
Working capital, net
1,105
12,881
Assumed long-term liabilities
(1,270
Other assets/liabilities, net
(897
Total estimated purchase price
106,280
The fair value of all the above assets acquired and liabilities assumed are preliminary in nature since the fair value analyses are not yet complete. Changes to the allocation of the purchase price may occur as these analyses are completed.
Approximately
$64.2 million of goodwill was recorded related to the Iotron acquisition, representing the excess of the purchase price over estimated fair values of all the assets acquired and liabilities assumed. The fair values allocated to goodwill and tangible and intangible assets are deductible for tax purposes. The qualitative elements of goodwill primarily represent the expanded future growth opportunities for the combined company and the addition of Iotron’s highly skilled workforce. We recorded $14.0 million, $0.9 million, and $1.5 million for intangible assets as part of the acquisition related to customer relationships, proprietary technology, and employee non-compete agreements, respectively. The estimated useful lives of the identifiable finite-lived intangible assets range from 5 to 15 years.
Iotron’s results of operations are included in our consolidated financial statements from the date of the transaction within the Sterigenics segment. The unaudited pro forma consolidated results for the nine-month periods ending September 30, 2020 and 2019, are reflected in the pro forma table below had the transaction occurred on January 1, 2019. The following unaudited supplemental pro forma financial information is based on our historical consolidated financial statements and Iotron’s historical consolidated financial statements, as adjusted for amortization of acquired intangible assets, an increase in interest expense resulting from interest on the First Lien Notes to finance the acquisition, and to reflect the change in the estimated income tax rate for federal and state purposes.
A-8
Nine months ended September 30,
Nine Months Ended September 30,
Net revenues
616,144
598,935
7,840
4,941
Net revenues and net income from the Iotron acquisition included in the Company’s results since July 31, 2020, the date of the acquisition, were $3.6 million and $0.9 million, respectively.
In connection with the Iotron acquisition, we incurred approximately
$2.8 million in transaction costs for the nine months ended September 30, 2020, which were included in selling, general and administrative expenses in the consolidated statements of operations and comprehensive income (loss).
We refer to your "Key Strengths" and "Our Strategy" sections in the Summary. For balance, please revise so that your Summary risks disclosure is of the same prominence and features a corresponding level of discussion and specificity as these other sections.Rest of the question
For example, expand your disclosure to discuss your EO emissions legal proceedings, including that your per occurrence limit for claims relating to Willowbrook EO emissions has been reached, and that additional EO lawsuits have been filed recently. Additional examples include expanding your disclosures regarding your total long-term debt and stockholders' agreement.
Inventory consists primarily of the following:Read in the reply
September 30, 2020
December 31, 2019
Raw materials and supplies
22,385
29,640
Work-in-process
1,067
1,961
Finished goods
5,795
5,892
29,247
37,493
Reserve for excess and obsolete inventory
(94
(97
The inventories as of September 30, 2020 and December 31, 2019 are held at Nordion.
We note your disclosures relating to the Sponsors' concentrated ownership. Please expand your risk factor disclosures as appropriate to discuss other interests that may conflict between the Sponsors and your other shareholders, such as recent distributions they have received, and may receive in connection with the offering, and add a corresponding discussion in your Summary.Rest of the question
We note, for example, your disclosure on page F-39 that the effect of the conversion of Topco Parent units will result in a material increase of loss per share. Our substantial leverage could adversely affect our ability to raise additional capital to fund our operations..., page 38
Prepaid Expenses and Other Current AssetsRead in the reply
Prepaid expenses and other current assets consist primarily of the following:
Please quantify your debt service requirements and disclose the percentage of your cash flow that must be dedicated to debt service, both principle and interest. A lowering or withdrawal of the ratings assigned to our debt. . . , page 40
Property, Plant and EquipmentRead in the reply
As discussed in the Commitments and Contingencies note, we have been involved in litigation related to our ethylene oxide sterilization operations in
Willowbrook, Illinois. On September 30, 2019, we announced plans to exit our operations in Willowbrook citing the unstable legislative and regulatory landscape in Illinois as well as the expiration of the primary Willowbrook facility lease.
Prior to this decision, we had approximately $9.8 million in net book value of fixed assets at the Willowbrook facilities, including $1.8 million of construction in process.Rest of the answer
Based on our initial assessment of fixed assets that can be transferred to other Sterigenics’ facilities, we recorded a fixed asset impairment of approximately $5.8 million as recognized in “Impairment of long-lived assets” in the consolidated statement of operations and comprehensive income (loss) for the nine months ended September 30, 2019. Further, in conjunction with the decision not to reopen our Willowbrook facilities, we incurred certain restructuring costs consisting of employee termination benefits totaling
$1.1 million in the nine months ended September 30, 2019. The $1.1 million in costs represents all termination benefits costs expected to be incurred in connection with the Willowbrook closure, and were included in “Cost of revenues” on the consolidated statement of operations and comprehensive income (loss) and are included in our Sterigenics segment. Decommissioning of the Willowbrook facilities began in October 2019 and is anticipated to take until the end of
2020. At September 30, 2020 and December 31, 2019, we had an asset retirement obligation of approximately $0.6 million and $2.2 million representing our estimate of the costs to decommission the Willowbrook operations. This liability is included in “Current portion of asset retirement obligations” and “Noncurrent asset retirement obligations” within the consolidated balance sheets.
Please revise to specify your debt's ratings.
Goodwill and Other Intangible AssetsRead in the reply
Changes to goodwill for the nine months ended September 30, 2020 were as follows:
Goodwill at December 31, 2019
612,689
281,890
141,286
Iotron acquisition, preliminary estimate
Changes due to foreign currency exchange rates
(2,812
(7,278
1,571
(8,519
Goodwill at September 30, 2020
674,112
274,612
142,857
Other intangible assets consist of the following as of:
Gross
Carrying
Amortization
Finite-lived intangible assets
Customer relationships
628,115
292,310
Proprietary technology
88,627
35,527
Trade name
144
Land-useRest of the answer
rights
9,111
Sealed source and supply agreements
229,579
84,688
1,848
392
Total finite-lived intangible assets
957,424
414,212
Indefinite-lived intangible assets
Regulatory licenses and other (1)
78,021
Trade name / trademark
25,895
Total indefinite-lived intangible assets
103,916
1,061,340
A-10
612,068
248,931
87,971
30,224
7,201
1,860
8,896
1,011
235,706
74,825
336
243
952,178
357,094
80,103
20,819
100,922
1,053,100
(1)
Includes certain transportation certifications, a class 1B nuclear license and other intangibles related to obtaining such licensure. These assets are considered indefinite-lived as the decision for renewal by the Canadian Nuclear Safety Commission is highly based on a licensee’s previous assessments, reported incidents, and annual compliance and inspection results. New applications for license can take a significant amount of time and cost; whereas an existing licensee with a historical record of compliance and current operating conditions more than likely ensures renewal for another 10 year license period as Nordion has demonstrated over its 70 years of history.
Amounts include the impact of foreign currency translation. Fully amortized amounts are written off.
Amortization expense for other intangible assets was $59.8 million and $60.0 million for the nine months ended September 30, 2020 and 2019, respectively. Of the amortization expense referenced above, $15.8 million and $16.1 million is included in “Cost of revenues” for the nine months ended September 30,
2020 and 2019, respectively. The remainder of the amortization in each of the aforementioned periods is included in “Selling, general and administrative expenses” in the consolidated statements of operations and comprehensive income
(loss).
The estimated aggregate amortization expense for finite-lived intangible assets for each of the next five years and thereafter is as follows:
For the remainder of 2020
20,181
2021
81,065
2022
77,215
2023
77,208
2024
76,432
Thereafter
211,111
543,212
The weighted-average remaining useful life of the finite-lived intangible assets was approximately 10 years as of
September 30, 2020.
We note the statement that you undertake no obligation to update forward-looking statements publicly in light of new information or future events. Please revise to clarify that you will update this information to the extent required by law.
Accrued liabilities consist of the following at:Read in the reply
Please disclose the interest rate and maturity date for each item of indebtedness to be discharged using the proceeds of the offering. If the indebtedness to be discharged was incurred within one year, describe the use of the proceeds of such indebtedness. Refer to Instruction 4 to Item 504 of Regulation S-K.
Long-term debt obligations consist of the following:Read in the reply
Term loan, due 2026
2,109,400
2,120,000
Senior notes, due 2027
770,000
Senior notes, due 2026
100,000
Other long-term debt
450
881
Total debt
2,979,850
2,890,881
Less current portion
(21,200
(16,331
Less unamortized debt issuance costs and debt discounts
(69,870
(73,677
Total long-term debt, less current portion and debt issuance costs and debt discounts
Debt Facilities
Senior Secured Credit Facilities
On December 13,
2019, Sotera Health Holdings, LLC (“SHH”), our wholly owned subsidiary, entered into new seniorRest of the answer
secured first lien credit facilities (the “Senior Secured Credit Facilities”) and settled its previously outstanding term loan and senior notes.
The Senior Secured Credit Facilities consist of both a senior secured first lien term loan (the “Term Loan”) and a
$190.0 million senior secured first lien revolving credit facility (the “Revolving Credit Facility”). The Term Loan matures on December 13, 2026, and the Revolving Credit Facility matures on December 13, 2024. The Senior
Secured Credit Facilities also provide SHH the right at any time and under certain conditions to request incremental term loans or incremental revolving credit commitments based on a formula defined in the Senior Secured Credit Facilities. As of
September 30, 2020, total borrowings under the Term Loan were $2,109.4 million.
Beginning on June 30, 2020, the Term Loan is paid in equal quarterly installments in aggregate annual amounts equal to 1.00% of the Term Loan original principal amount, while the remaining balance matures on December 13, 2026. The Term Loan may bear interest at LIBOR or an alternate base rate
(“ABR”) subject to a 1.00% floor plus, an incremental margin of 4.50% in the case of LIBOR loans and 3.50% in the case of ABR loans. The weighted average interest rate on borrowings under the Term Loan at September 30, 2020 was 5.50%.
As of September 30, 2020, and December 31, 2019, capitalized debt issuance costs totaled $4.3 million and $4.7 million, respectively, and debt discounts totaled $39.3 million and $44.0 million, respectively, related to the Senior Secured Credit Facilities. Such costs are recorded as a reduction of debt on our consolidated balance sheets and amortized as a component of interest expense over the term of the debt agreement.
A-12
Borrowings under the Revolving Credit Facility bear interest at a rate per annum equal to an applicable margin, plus, at our option, either (a) an ABR or (b) a LIBOR rate. The applicable margin under the Revolving Credit Facility may be reduced by reference to a leverage-based pricing grid with step-downs of 0.25% at a specified senior secured first lien net leverage ratio. In addition to paying interest on any outstanding borrowings under the Revolving Credit Facility, SHH is required to pay a commitment fee to the lenders under the Revolving Credit Facility in respect of the unutilized commitments thereunder and customary letter of credit fees. The Revolving Credit Facility contains a maximum senior secured first lien net leverage ratio covenant of 9.00 to 1.00, tested on the last day of each fiscal quarter if, on the last day of such fiscal quarter, the sum of (i) the aggregate principal amount of the revolving loans then outstanding under the Revolving Credit Facility, plus (ii) the aggregate amount of letter of credit (“LC”) disbursements that have not been reimbursed within two business days following the end of the fiscal quarter, exceeds the greater of $76.0 million and 40.0% of the aggregate principal amount of the revolving commitments then in effect. Although this covenant did not apply as the conditions were not met, as of September 30, 2020 the first lien net leverage ratio, as defined in the Revolving Credit Facility, was approximately 5.10 to 1.00.
As of September 30, 2020, there were no borrowings on the Revolving Credit Facility. SHH borrowed $50.0 million on the Revolving Credit Facility during the first quarter of 2020 which was repaid in the second quarter of 2020. The interest rate on the borrowings under the Revolving Credit Facility averaged approximately 5.0%.
The Senior Secured Credit Facilities contain additional covenants that, among other things, restrict, subject to certain exceptions, our ability and the ability of our restricted subsidiaries to engage in certain activities, such as incur indebtedness or permit to exist any lien on any property or asset now owned or hereafter acquired, as specified in the debt facility. The Senior Secured Credit
Facilities also contain certain customary affirmative covenants and events of default, including upon a change of control. As of September 30, 2020, we were in compliance with all the Senior Secured Credit Facilities covenants.
All of SHH’s obligations under the Senior Secured Credit Facilities are unconditionally guaranteed by the Company and each existing and subsequently acquired or organized direct or indirect wholly-owned domestic restricted subsidiary of SHH, with customary exceptions including, among other things, where providing such guarantees is not permitted by law, regulation or contract or would result in material adverse tax consequences. All obligations under the Senior Secured Credit Facilities, and the guarantees of such obligations, are secured by substantially all of the assets of the borrower and guarantors, subject to permitted liens and other exceptions and exclusions, as outlined in the Senior Secured Credit Facilities.
Outstanding letters of credit are collateralized by encumbrances against the Revolving Credit Facility and the collateral pledged thereunder, or by cash placed on deposit with the issuing bank. As of September 30, 2020, the Company had $64.3 million of letters of credit issued against the
Revolving Credit Facility, resulting in total availability under the Revolving Credit Facility of $125.7 million.
First Lien Notes
On July 31, 2020, SHH issued $100.0 million aggregate principal amount of senior secured first lien notes due 2026 (the “First Lien
Notes”), which mature on December 13, 2026. The First Lien Notes bear interest at a rate equal to LIBOR subject to a 1.00% floor plus 6.00% per annum. Interest is payable on a quarterly basis with no principal due until maturity. The weighted average interest rate on the First Lien Notes at September 30, 2020 was 7.00%.
SHH is entitled to redeem all or a portion of the First Lien
Notes, at any time and from time to time, subject to certain premiums depending on the date of redemption: any time on or prior to July 31, 2021, a customary make-whole premium applies and, thereafter, specified premiums that decline to zero apply (in each case as described in the indenture governing the First Lien Notes).
All of SHH’s obligations under the First Lien Notes are unconditionally guaranteed by the Company and each existing and subsequently acquired or organized direct or indirect wholly-owned domestic restricted subsidiary of SHH, with customary exceptions including, among other things, where providing such guarantees is not permitted by law, regulation or contract or would result in material adverse tax consequences. All obligations under the First Lien Notes, and the guarantees of such obligations, are secured by substantially all of the assets of the borrower and guarantors, subject to permitted liens and other exceptions and exclusions, as outlined in the First Lien Notes. Such collateral is substantially the same collateral that secures the Senior Secured Credit Facilities and Second Lien
Notes. Such collateral securing the First Lien Notes ranks pari passu with that of the Senior Secured Credit Facilities and has priority over the collateral securing the Second Lien Notes.
A-13
At September 30, 2020, capitalized debt issuance costs were $0.7 million and debt discounts were $2.9 million, respectively, related to the First Lien Notes, which are recorded as a reduction of debt on our consolidated balance sheets and amortized into interest expense over the term of the debt agreement.
Second Lien Notes
On December 13, 2019, SHH issued
$770.0 million aggregate principal amount of senior secured second lien notes due 2027 (the “Second Lien Notes”), which mature on December 13, 2027. The Second Lien Notes bear interest at a rate equal to LIBOR subject to a 1.00% floor plus 8.00% per annum. The weighted average interest rate on the Second Lien Notes at September 30, 2020 was 9.00%.
SHH is entitled to redeem all or a portion of the Second Lien Notes, at any time and from time to time, subject to certain premiums depending on the date of redemption: any time on or prior to December 13, 2020, a customary make-whole premium applies and, thereafter, specified premiums that decline to zero apply (in each case as described in the indenture governing the Second Lien Notes). In addition, under certain circumstances, such as an initial public offering or certain changes of control, SHH has certain additional redemption rights (as described in the indenture governing the Second Lien Notes).
All of SHH’s obligations under the Second Lien Notes are unconditionally guaranteed by the Company and each existing and subsequently acquired or organized direct or indirect wholly-owned domestic restricted subsidiary of SHH, with customary exceptions including, among other things, where providing such guarantees is not permitted by law, regulation or contract or would result in material adverse tax consequences. All obligations under the Second Lien Notes, and the guarantees of such obligations, are secured by substantially all of the assets of the borrower and guarantors, subject to permitted liens and other exceptions and exclusions, as outlined in the Second Lien Notes. Such collateral is substantially the same collateral that secures the Senior Secured Credit Facilities and the
First Lien Notes, and any security interest or lien on shared collateral securing the Senior Secured Credit Facilities or the First Lien Notes shall have priority over any security interest or lien on shared collateral securing the Second Lien
Notes.
At September 30, 2020 and December 31, 2019, capitalized debt issuance costs were $1.6 million and $1.8 million and debt discounts were $21.0 million and $23.2 million, respectively, related to the Second Lien notes, which are recorded as a reduction of debt on our consolidated balance sheets and amortized into interest expense over the term of the debt agreement.
On page 128, you disclose that upon the occurrence of a change of control, all then outstanding unvested Class B-1 Units held by Unitholders will become vested as of the date of consummation of such change of control.Rest of the question
In addition, on page 64, you disclose that you expect to recognize the remaining expense associated with the performance vesting awards "upon the listing and public trading of your common stock." Please tell us why stock compensation expense is not reflected as a pro forma adjustment in the capitalization table.
Income tax expense is provided on an interim basis based upon our estimate of the annual effective income tax rate. In determining the estimated annual effective income tax rate, we analyze various factors, including projections of our annual earnings and the taxing jurisdictions where the earnings will occur, the impact of state and local taxes, our ability to utilize tax credits and net operating loss carryforwards and available tax planning alternatives.Read in the reply
Our effective tax rate was (255.9%) and 63.3% for the nine months ended September 30, 2020 and 2019, respectively.Rest of the answer
Income tax expense (benefit) for the nine months ended September 30, 2020 and 2019 differs from the statutory rate primarily due to the impact of global intangible low-taxed income (“GILTI”) (including final 951A regulations), the foreign rate differential, and non-deductible expenses.
On March 27, 2020, the Coronavirus Aid, Relief, and
Economic Security Act (the “CARES Act”) was enacted in response to the COVID-19 pandemic, and among other things, provides tax relief to businesses. Tax provisions of the CARES Act include retroactive increases in the limitation on the deductibility of interest expense from 30% to 50% for tax years beginning in 2019 or 2020, and other provisions. As a result of the increased limitation on the deductibility of interest expense, we recognized a current tax benefit of $8.7 million in the nine months ended September 30, 2020 related to 2019 interest expense previously recorded as deferred. In addition, we currently estimate an additional $8.2 million current tax benefit for the 2020 tax year, which will be recognized in the fourth quarter. The increased limitation under the CARES Act resulted in a first quarter 2020 reversal of the $5.6 million valuation allowance recorded at the end of the 2019 tax year.
A-14
On July 23, 2020, final 951A regulations were published that exempts income subject to a high rate of foreign tax from inclusion as GILTI for tax years beginning after December 31, 2017. The reduction in Adjusted Taxable Income (“ATI”) realized as a result of the final 951A regulations resulted in a $36.2 million valuation allowance recorded in the quarter ended September 30, 2020.
Our current estimate of 2020 current tax expense related to GILTI is
$1.5 million, a reduction of $11.2 million from prior estimates, and is considered as a component of our estimated annual effective tax rate calculation. In 2019 and 2018, we recognized GILTI current tax expense of $10.3 million and
$5.6 million, respectively. As a result of final 951A regulations, the 2019 and 2018 GILTI tax was reduced to $2.4 million and $0, respectively, and was recognized as a reduction to income tax expense in the third quarter of 2020.
Once you have an estimated offering price or range, please explain to us how you determined the fair value of the common stock underlying your equity issuances and the reasons for any differences between the recent valuations of your common stock leading up to the IPO and the estimated offering price.Rest of the question
This information will help facilitate our review of your accounting for equity issuances including stock compensation and beneficial conversion features. Please discuss with the staff how to submit your response.
The Company sponsors various post-employment benefit plans including, in certain countries outside the U.S., defined benefit and defined contribution pension plans, retirement compensation arrangements, and plans that provide extended health care coverage to retired employees, the majority of which relate to Nordion.Read in the reply
Defined benefit pension plan
The interest cost and expected return on plan assets are recorded in “Other income, net” and the service cost component is included in the same financial statement line item as the applicable employee’s wages in the consolidated statements ofRest of the answer
operations and comprehensive income (loss). The components of net periodic pension cost for the plans for the nine months ended
September 30, 2020 and 2019 were as follows:
Nine months ended
Pension
Service cost
821
859
Interest cost
5,974
6,379
Expected return on plan assets
(10,712
(9,896
Amortization of net actuarial (gain) loss
588
Net periodic (benefit) cost
(3,329
(2,658
Other benefit plans
Other benefit plans include a supplemental retirement arrangement, a retirement and termination allowance, and post-retirement benefit plans, which include contributory health and dental care benefits and contributory life insurance coverage. All non-pension post-employment benefit plans are unfunded.
The components of other post-retirement benefit plans for the nine months ended September 30, 2020 and 2019 were as follows:
Other post-retirement benefits
218
236
(16
278
We currently expect funding requirements of approximately $3.0 million in each of the next five years to fund the regulatory solvency deficit, as defined by Canadian federal regulation, which require solvency testing on defined benefit pension plans.
We may obtain a qualifying letter of credit for solvency payments, up to 15% of the market value of solvency liabilities as determined on the valuation date, instead of paying cash into the pension fund. As of September 30, 2020, and December 31, 2019, we had letters of credit outstanding totaling $42.8 million and $41.0 million, respectively, related to these liabilities. The deficit has decreased due to an increase in the value of the pension assets more than the increase in the value of pension liabilities. The actual funding requirements over the five-year period will be dependent on subsequent annual actuarial valuations. These amounts are estimates, which may change with actual investment performance, changes in interest rates, any pertinent changes in Canadian government regulations, and any voluntary contributions.
For each of the periods presented, please quantify the impact each of the factors identified had on each of the components of your results of operations as well as your segment operations beginning on page 73. Refer to Item 303 of Regulation S-K.
Other Comprehensive Income (Loss)Read in the reply
Changes in our accumulated other comprehensive income (loss) balances, net of tax, were as follows:
Nine Months Ended September 30, 2020
Benefit
Plans
Foreign
Currency
Translation
Interest
Rate
Swaps
Beginning balance – January 1, 2020
(27,113
(67,453
179
Other comprehensive income (loss) before reclassifications
(5,234
(35,421
Amounts reclassified from accumulated other comprehensive income (loss)
5,055
Net current-period other comprehensive income (loss)
(30,366
Ending balance – September 30, 2020
(26,413
(98,340
Nine Months EndedRest of the answer
September 30, 2019
Beginning balance – January 1, 2019
(14,987
(94,970
11,068
Ending balance – September 30, 2019
(15,396
(84,002
We note your disclosure stating that the increase in cash provided by operating activities from fiscal year 2018 to fiscal year 2019 was driven by "strong operating performance". Please expand your disclosure to quantify and discuss in further detail the underlying reasons for the changes reported in your Statements of Cash Flows, which contributed to a stronger operating performance.Rest of the question
Refer to Item 303(a)(1) of Regulation S-K and FRC Section 501.13.b and 13.b.1 for guidance.
In April 2020, the Company approved a loan to a member of management for approximately $0.5 million to assist with personal taxes incurred on share-based grants received. The loan is collateralized by the shares, and proceeds of distributions will be applied against the loan.Read in the reply
The immediate family of a member of management are 25% owners of a facility that is under lease by the Company through June 2024, with one five-year renewal option through June 2029.Rest of the answer
The rental expense related to this facility is approximately $1.0 million per year.
In addition, we do business with a number of other companies affiliated with Warburg Pincus and GTCR, our Sponsors. All transactions with these companies have been conducted in the ordinary course of our business and are not material to our operations.
Please include a description of the facility lease with an immediate family member of management that is described on pages F-36 and F-72 or tell us why such disclosure is not required. Notes to Consolidated Financial Statements 8. Goodwill and Other Intangible Assets, page F-20
The Company’s equity-based awards issued to employees include restricted unit awards which vest based on either time or the achievement of certain performance and market conditions. These equity-based awards represent an interest in our parent, Sotera Health Topco Parent, L.P. (“Topco Parent”), and are granted in respect of services provided to the Company and its subsidiaries.Read in the reply
Compensation expense resulting from time vesting based awards is recognized in our consolidated statements of operations and comprehensive income (loss), primarily within “Selling, general and administrativeRest of the answer
expenses,” at grant date fair value over the requisite service period (typically five years on a straight-line basis for time vested awards). Compensation expense resulting from performance awards that vest upon satisfaction of a performance condition is recognized at grant date fair value when the performance condition is deemed probable, which may cause volatility in the timing of expense recognition. The calculated compensation expense for performance awards is adjusted based on an estimate of awards ultimately expected to vest. For awards with market conditions, the market condition is taken into account when calculating grant date fair value.
A-16
Class B-1 time vesting units vest on a daily basis pro rata over a five-year period (20% per year), subject to the grantee’s continued services on each vesting date. Upon the occurrence of a change of control of the Company, all then outstanding unvested Class B-1
Units held by Unitholders will become vested as of the date of consummation of such change of control, subject to the Unitholder’s continued services through the consummation of the change of control.
Class B-2 Units are considered performance vesting units, and are scheduled to vest only upon satisfaction of certain thresholds. These units vest as of the first date on which (i) our Sponsors have received two and one-half times their invested capital in Topco Parent and (ii) the Sponsors’ internal rate of return exceeds twenty percent, subject to such grantee’s continued services through such date. No compensation expense has been recorded on the Class B-2 Units at this time as the related performance conditions are not considered probable of achievement. In the event of a change in control of the Company, any outstanding Class B-2 Units that remain unvested immediately following the consummation of such a change in control of the Company shall be immediately canceled and forfeited without compensation.
Class C Units were issued in June 2016, are considered performance and time vesting units, and were accounted for as liability awards. No compensation expense was recorded on the Class C Units prior to the third quarter of 2019, as the related performance conditions were not considered probable of achievement. In the third quarter of 2019, all Class C Units vested based on the achievement of the aggregate distributions to the Class A Unitholders and approval of the board of managers of Topco Parent for accelerated vesting, and $10.0 million of stock-compensation expense was recognized and paid in accordance with the terms for redemption of outstanding Class C Units. No Class C Units remain outstanding.
The Company recognized $4.0 million and $15.1 million ($10.0 million related to Class C Units and $5.1 million related to Class B-1 Units) of share-based compensation for the nine months ended September 30, 2020 and 2019, respectively.
Fair value of the Class B-1 time vesting and B-2 performance vesting units is estimated on the date of grant using a simulation-based option valuation model incorporating multiple and variable assumptions over time, including assumptions such as employee forfeitures, unit price volatility and dividend assumptions.
A summary of the activity for the nine months ended September 30, 2020 related to the Class B-1 and B-2 units issued is presented below:
B-1 Time
Vesting
B-2
Performance
As of December 31, 2019
14,450,263
15,011,256
Granted
11,450,000
Forfeited
(84,390
(407,381
Vested
(10,201,706
Please disclose when the initial amounts of customer relationships, proprietary technology, and sealed source and supply agreements were initially recorded and the transaction in which they were initially established.
Supplemental Pro Forma Earnings Per Share (unaudited)Read in the reply
As further discussed in the Subsequent Events note, on November [ ], 2020, the Company effected a [ ]-for-one stock split of its outstanding common stock. The unaudited supplemental pro forma earnings per share data for the nine months ended
September 30, 2020 is presented below giving effect to the stock split.
Under SEC SAB Topic 1.B.3, a dividend declared in the latest year would be deemed to be in contemplation of the offering with the intention of repayment out of offering proceeds to the extent that the dividend exceeded earningsRest of the answer
during the previous twelve months. During the year ended December 31, 2019, the Company paid $691.2 million of dividends, which exceeded the $20.9 million of net loss attributable to Sotera Health Company for the year ended December 31, 2019. As the Company had a net loss for the year ended December 31, 2019, no amount of the dividend was considered paid out of recent earnings, and as such, the unaudited supplemental pro forma earnings per share and pro forma equivalent shares give effect to the issuance of the number of shares that would be required to generate net proceeds sufficient to make the dividends of $691.2 million in 2019. The number of incremental shares that
A-17 would be required to be issued to pay the dividend is based on the assumed initial public offering price of $[●] per share, the midpoint of the estimated offering price range set forth on the cover of the Company’s prospectus after deducting estimated underwriting discount and commissions and estimated offering expenses of $[●] per share. As a result, [●] shares to be issued in the offering (the estimated proceeds from which are greater than the amount by which the 2019 dividends exceeded earnings) have been included in the denominator for purposes of pro forma earnings per share calculations for the nine months ended September 30, 2020.
The following table sets forth a computation of unaudited supplemental pro forma basic and diluted earnings per share for the nine months ended
September 30, 2020:
(unaudited)
Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications.
We lease certain facilities and equipment under various non-cancelable operating leases that expire through October 2034. Most of our real property leases provide for renewal periods and rent escalations and stipulate that we pay taxes, maintenance, and certain other operating expenses applicable to the leased premises.Read in the replyRest of the answer
We made an accounting policy election whereby leases with an initial term of 12 months or less are recognized as lease expense on a straight-line basis over the lease term and not recorded on the consolidated balance sheet.
We determine if an agreement contains a lease and classify our leases as operating or finance at the lease commencement date. Finance leases are those in which we will pay substantially all the underlying asset’s fair value or will use the asset for all or a major part of its economic life, including circumstances in which we will ultimately own the asset. Lease assets arising from finance leases are included in “Property, plant and equipment, net” and the liabilities are included in “Finance lease obligations” on the consolidated balance sheets. For finance leases, we recognize interest expense using the effective interest method and we recognize amortization expense on the lease asset over the shorter of the lease term or the useful life of asset. Finance leases are accounted for as if the assets were owned and financed, with associated expense recognized in “Interest expense, net” and “Cost of revenues” or “Selling, general and administrative expenses” within the consolidated statements of operations and comprehensive income (loss) depending on the nature of the underlying asset.
Operating lease assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term. Lease assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. As most leases do not provide an implicit interest rate, we estimate an incremental borrowing rate to determine the present value of lease payments. Our estimated incremental borrowing rate reflects a secured rate based on recent debt issuances, our estimated credit rating, and lease term.
We recognize operating lease costs on a straight-line basis over the term of the lease in “Cost of revenues” or “Selling, general and administrative expenses” on the consolidated statements of operations and comprehensive income (loss) depending on the nature of the underlying asset. Non-lease components are accounted for separately from the lease components for all asset classes.
The components of lease expense were as follows for the nine months ended September 30, 2020:
Operating lease costs
10,610
Finance lease costs:
Amortization of right of use assets
1,930
Interest on lease liabilities
1,423
Total finance lease costs
3,353
Total lease costs
13,963
Includes $0.7 million of short-term lease costs in the nine-months ended September 30, 2020.
A-18
Operating lease expense for the nine months ended September 30, 2019 was $10.6 million.
Lease terms and discount rates were as follows:
Weighted average remaining lease term:
Operating leases
6.6 years
Finance leases
16.3 years
Weighted average discount rate:
6.16
%
6.13
Supplemental cash flow information related to leases was as follows:
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases
9,048
Operating cash flow for finance leases
1,562
Finance cash flows for finance leases
1,116
Maturities of lease liabilities as of September 30, 2020 are as follows:
Operating
Leases
Finance
Remainder of 2020
3,216
788
4,004
11,610
3,134
14,744
10,480
2,979
13,459
8,484
2,995
11,479
5,894
3,047
8,941
2025 and Thereafter
21,144
37,911
59,055
Total lease payments
60,828
50,854
111,682
Less imputed interest
(11,539
(19,067
(30,606
We note your response to prior comment 5. As previously noted, please further balance your Summary section by expanding your summary risks disclosure, including by expanding the seventh bullet on page 10 to specify your total amount of debt and the percentage of your cash flow that must be dedicated to debt service (both principal and interest).Rest of the question
Additionally, please balance your disclosures in the second full paragraph on page 7 regarding revenue growth by also noting you had net losses for fiscal years 2018 and 2019.
to the Staff’s comment, the Company has revised the disclosure on page 10.Read in the reply
We note your disclosures in the prospectus stating that your amended and restated certificate of incorporation provides that derivative actions will be brought in the Court of Chancery, or any state or federal court located within the State of Delaware if the Court of Chancery does not have jurisdiction.Rest of the question
However, the exclusive forum provision set forth in your Exhibit 3.1 does not include the reference to a federal court if the Court of Chancery does not have jurisdiction. Please revise to clarify whether this provision applies to actions arising under the Exchange Act, and please also ensure that the exclusive forum provision in the governing documents states this clearly, or tell us how you will inform investors in future filings that the provision does not apply to any actions arising under the Exchange Act.
to the Staff’s comment, the Company has revised Exhibit 3.1 and the disclosures on pages 52 and 170.Read in the reply
Also in this review: company letter, Nov 4, 2020, company letter, Nov 10, 2020, company letter, Nov 17, 2020, company letter, Nov 17, 2020, company letter, Mar 15, 2021, company letter, Mar 15, 2021